ARIBIO Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.aribio.com
Clinical Trials
3
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AriBio Co., Ltd.
- Target Recruit Count
- 1150
- Registration Number
- NCT05531526
- Locations
- 🇺🇸
IMA Clinical Research Phoenix, Phoenix, Arizona, United States
🇺🇸Perseverance Research Center, LLC, Scottsdale, Arizona, United States
🇺🇸Clinical Endpoints - N. Scottsdale, Scottsdale, Arizona, United States
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- AriBio Co., Ltd.
- Target Recruit Count
- 210
- Registration Number
- NCT03625622
- Locations
- 🇺🇸
Advanced Clinical Research, Inc., West Jordan, Utah, United States
🇺🇸Northern California Research, Sacramento, California, United States
🇺🇸Syrentis Clinical Research, Santa Ana, California, United States
News
AriBio and Fujirebio Complete Major Biomarker Sample Collection for Alzheimer's Research in Phase 3 POLARIS-AD Trial
AriBio and Fujirebio Diagnostics have completed a significant biomarker sample collection from over 1,150 participants in the Phase 3 POLARIS-AD trial for early Alzheimer's disease.